Perrigo Company plc Payments to Acquire Productive Assets
Perrigo Company plc (PRGO) reported Payments to Acquire Productive Assets of $149.10 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireProductiveAssets · last filed 2020-02-27
- Perrigo Company plc payments to acquire productive assets for the quarter ending 2019-12-31 was $62.90M, a 2146.43% increase year-over-year.
- Perrigo Company plc payments to acquire productive assets for the quarter ending 2019-09-28 was $51.20M.
- Perrigo Company plc payments to acquire productive assets for the quarter ending 2018-12-31 was $2.80M.
- Perrigo Company plc payments to acquire productive assets for fiscal 2019 was $149.10M, a 318.82% increase from fiscal 2018.
- Perrigo Company plc payments to acquire productive assets for fiscal 2018 was $35.60M.
- Perrigo Company plc payments to acquire productive assets for fiscal 2017 was $0.00.
| Period end | Payments to Acquire Productive Assets 3 month | Payments to Acquire Productive Assets 6 month | Payments to Acquire Productive Assets 9 month | Payments to Acquire Productive Assets 12 month |
|---|---|---|---|---|
| 2019-12-31 | $62.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $114.10M derived: sum of 2 quarters · filed 2020-02-27 | $149.10M 10-K · filed 2020-02-27 | |
| 2019-09-28 | $51.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $86.20M 10-Q · filed 2019-11-06 | ||
| 2019-06-29 | $35.00M 10-Q · filed 2019-08-08 | |||
| 2018-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $35.60M 10-K · filed 2020-02-27 | ||
| 2018-09-29 | $32.80M 10-Q · filed 2019-11-06 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |